Efficacy and safety of baricitinib versus azathioprine, both combined with topical corticosteroids, in patients with moderate-to-severe atopic dermatitis: a single-centre randomized open-label trial

Mohammad Malekan(Tehran University of Medical Sciences), Parmida Gouran(Mazandaran University of Medical Sciences), Mohammad Mahdi Parvizi(Shiraz University of Medical Sciences), Mahsa Mollapour Sisakht(Biotechnology Research Center), Saeid Taghiloo(Mazandaran University of Medical Sciences), Nasim Gholizadeh(Mazandaran University of Medical Sciences), Afsaneh-Sadat Rostamkolaei(Mazandaran University of Medical Sciences), Abbas Dabbaghzadeh(Mazandaran University of Medical Sciences), Reza Alizadeh‐Navaei
British Journal of Dermatology
November 13, 2025
10.1093/bjd/ljaf456
Cited by 1

Related Papers

Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
|The Lancet|2017|13.5k
Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016
|The Lancet|2017|4.9k
Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
|The Lancet|2017|2.4k
Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
|The Lancet|2017|2.2k
Evolution and patterns of global health financing 1995–2014: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries
|The Lancet|2017|296